July 17, 2019 10:22 AM EDTUpdated 02:28 PM

Seer entices ex FDA commissioner McClellan to its board; Vanda tests tradipitant in motion sickness study

Natalie Grover

Reporter

→ The revolving door between government and the biopharmaceutical industry is spinning. On Wednesday, life sciences and health data company Seer unveiled that it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Seer entices ex FDA commissioner McClellan to its board; Vanda tests tradipitant in motion sickness study

Natalie Grover

Reporter

Sign up to read this article for free.

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Seer en­tices ex FDA com­mis­sion­er Mc­Clel­lan to its board; Van­da tests tradip­i­tant in mo­tion sick­ness study

Natalie Grover

Reporter

Sign up to read this article for free.

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

FDA says Ozem­pic, We­govy short­age is over

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Seer entices ex FDA commissioner McClellan to its board; Vanda tests tradipitant in motion sickness study

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence